A new protocol for multiple inhalation of IFN-γ successfully treats MDR-TB: A case study

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 6, 2008, Pages 636-644

  Grahmann, P R ^a   Braun, R K ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

T cells; Inhaled IFN ; Multidrug resistant tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ANTIINFECTIVE AGENT; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; GAMMA INTERFERON; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RECOMBINANT GAMMA INTERFERON; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

ADD ON THERAPY; ADULT; AEROSOL; ANAMNESIS; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; CELL DIVISION; CONTROLLED STUDY; CONVALESCENCE; DISEASE DURATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; PRIORITY JOURNAL; SPUTUM SMEAR; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AEROSOLS; ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; SPUTUM; T-LYMPHOCYTE SUBSETS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 45349092396     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Dye C, Bassili A, Bierrenbach A, et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis 2008 Jan 15 [epub ahead of print].
2. Figueroa-Munoz J, Palmer K, Poz M R, Blanc L, Bergström K, Raviglione M. The health workforce crisis in TB control: a report from high-burden countries. Human Resour Health 2005; 3:2.
3. Migliori G B, Loddenkemper R, Blasi F, Raviglione M C. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is 'science' enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427.
4. Blondal K. Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis. Bull World Health Organ 2007; 85: 387-390.
5. Chakrabarti B, Davies P D. Key issues in multidrug-resistant tuberculosis. Future Microbiol 2007; 2: 51-61.
6. Kim S J. Current problems of drug-resistant tuberculosis and its control. Kekkaku 2002; 77: 735-740.
7. Gandhi N R, Moil A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
8. Jaffe H A, Buhl R, Mastrangeli A, et al. Organ-specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung. J Clin Invest 1991; 88: 297-302.
9. Berrington W R, Hawn T R. Mycobacterium tuberculosis, macrophages and the innate immune response: does common variation matter? Immunol Rev 2007; 219: 167-186.
10. Dieli F, Caccamo N, Meraviglia S, et al. Reciprocal stimulation of gammadelta T-cells and dendritic cells during the anti-mycobacterial immune response. Eur J Immunol 2004; 34: 3227-3235.
11. Doffinger R, Jouanguy E, Dupuis S, et al. Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. J Infect Dis 2000; 181: 379-384.
12. Dupuis S, Doffinger R, Picard C, et al. Human interferon-gamma-mediated immunity is a genetically controlled continuous trait that determines the outcome of mycobacterial invasion. Immunol Rev 2000; 178: 129-137.
13. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 1999; 21: 370-378.
14. Chatte G, Panteix G, Perrin-Fayolle M, Pacheco Y. Aerosolized interferon gamma for Mycobacteriutn avium complex lung disease. Am J Respir Crit Care Med 1995; 152: 1094-1096.
15. Eisenberg B L, Taylor D D, Weese J L. Aerosolized gamma-interferon and lipopolysaccharide enhances cytotoxicity of murine pulmonary alveolar macrophages. J Immunother 1991; 10: 51-56.
16. Condos R, Rom W N, Schluger N W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997; 349: 1513-1515.
17. Koh W J, Kwon O J, Suh G Y, et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 2004; 19: 167-171.
18. Roberts G D, Koneman E W, Kim Y K. Mycobacterium. In: Balows A, Hausler W J Jr, Hermann K L II, Isenberg D, Shadomy H J, eds. Manual of clinical microbiology. 5th ed. Washington DC, USA: American Society for Microbiology, 2001: pp 304-339.
19. Beige J, Lokies J, Schaberg T, et al. Clinical evaluation of a Mycobacteriutn tuberculosis PCR assay. J Clin Microbiol 1995; 33: 90-95.
20. Schroder K, Hertzog P J, Ravasi T, Hume D A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-189.
21. Darnell J E Jr, Kerr I M, Stark G R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
22. Reljic R. IFN-γ therapy of tuberculosis and related infections. J Interferon Cytokine Res 2007; 27: 353-364.
23. Hussain S, Zwilling B S, Lafuse W P. Mycobacteriutn avium infection of mouse macrophages inhibits IFN-γ Janus kinase-STAT signaling and gene induction by down-regulation of the IFN-γ receptor. J Immunol 1999; 163: 2041-2048.
24. Alvarez G R, Zwilling B S, Lafuse W P. Mycobacteriutn avium inhibition of IFN-γ signaling in mouse macrophages: toll-like receptor 2 stimulation increases expression of dominant-negative STAT1 beta by mRNA stabilization. J Immunol 2003; 171: 6766-6773.
25. Kincaid E Z, Ernst J D. Mycobacterium tuberculosis exerts gene-selective inhibition of transcriptional responses to IFN-γ without inhibiting STAT1 function. J Immunol 2003; 171: 2042-2049.
26. Yoshida A, Koide Y, Uchijima M, Yoshida T O. IFN-γ induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem Biophys Res Commun 1994; 198: 857-861.
27. Schierloh P, Yokobori N, Aleman M, et al. Mycobacterium tuberculosis-induced gamma interferon production by natural killer cells requires cross talk with antigen-presenting cells involving Toll-like receptors 2 and 4 and the mannose receptor in tuberculous pleurisy. Infect Immun 2007; 75: 5325-5337.
28. Deveci F, Akbulut H H, Celik I, Muz M H, Ilhan F. Lymphocyte subpopulations in pulmonary tuberculosis patients. Mediators Inflamm 2006; 2006: 89070.
29. Feng C G, Kaviratne M, Rothfuchs A G, et al. NK cell-derived IFN-γ differentially regulates innate resistance and neutrophil response in T-cell-deficient hosts infected with Mycobacterium tuberculosis. J Immunol 2006; 177: 7086-7093.
30. Yildiz P, Kadakal F, Tutuncu Y, et al. Natural killer cell activity in multidrug-resistant pulmonary tuberculosis. Respiration 2001; 68: 590-594.
31. Zahran W A, Ghonaim M M, Koura B A, El-Banna H, Ali S M, El-Sheikh N. Human natural killer T-cells (NKT), NK and T-cells in pulmonary tuberculosis: potential indicators for disease activity and prognosis. Egypt J Immunol 2006; 13: 67-78.
32. Ratcliffe L T, Lukey P T, MacKenzie C R, Ress S R. Reduced NK activity correlates with active disease in HIV patients with multidrug-resistant pulmonary tuberculosis. Clin Exp Immunol 1994; 97: 373-379.
33. O'Garra A, Vieira P. Regulatory T-cells and mechanisms of immune system control. Nat Med 2004; 10: 801-805.
34. Belkaid Y, Rouse B T. Natural regulatory T-cells in infectious disease. Nat Immunol 2005; 6: 353-360.
35. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4 + regulatory T-cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-352.
36. Kabelitz D, Bender A, Prospero T, Wesselborg S, Janssen O, Pechhold K. The primary response of human gamma/delta + T-cells to Mycobacterium tuberculosis is restricted to V gamma 9-bearing cells. J Exp Med 1991; 173: 1331-1338.
37. Nanno M, Shiohara T, Yamamoto H, Kawakami K, Ishikawa H. Gammadelta T-cells: firefighters or fire boosters in the front lines of inflammatory responses. Immunol Rev 2007; 215: 103-113.
38. Carvalho A C, Matteelli A, Airo P, et al. Gammadelta T lymphocytes in the peripheral blood of patients with tuberculosis with and without HIV co-infection. Thorax 2002; 57: 357-360.
39. Li B, Rossman M D, Imir T, et al. Disease-specific changes in gammadelta T-cell repertoire and function in patients with pulmonary tuberculosis. J Immunol 1996; 157: 4222-4229.